This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
Antonio Giordano | |
---|---|
Born | Naples, Campania, Italy | October 11, 1962
Nationality | Italian and American |
Alma mater | University of Naples Federico II |
Awards | Knight and Commander of Order of Merit of the Italian Republic; Cross of Merit Melitense from Sovereign Military Order of Malta |
Scientific career | |
Fields | Oncology |
Institutions |
|
Website | https://www.drantoniogiordano.com/ |
Antonio Giordano (Napoli, 11 October 1962) is an Italy oncologist, pathologist, geneticist, researcher and a professor. He became a naturalized American. Giordanio is the Director of the Sbarro Institute for Cancer Research and Molecular Medicine in Philadelphia and a professor for Anatomy and Pathological Histology at the Department of Medical Biotechnology at the University of Siena.
Giordano discovered some key factors in the regulation of the cell cycle and of mechanisms linked to the onset of tumors. In particular, he distinguished himself for having isolated the tumor suppressor gene, the RB2/p130, [1] [2] subsequently demonstrating how the same gene, introduced through a retrovirus in some animal models has been shown to reduce tumor growth. [3] He also works to communicate science to a general audience, particularly on topics concerning cancer risks associated with toxic waste in the Campania Region.
Antonio Giordano is the son of Giovan Giacomo Giordano (Corbara 1925 - 2010), an oncologist and pathologist of Maria Teresa Sgambati. He graduated with full marks in Medicine at the University of Naples in 1986. Giordano obtained his specialization in Anatomy and Pathological Histology from the University of Trieste. He later moved to United States for a PhD, where he was a student of Nobel Prize James Dewey Watson at Cold Spring Harbor Laboratory. [4] During his years there, Giordano discovered the direct link between cell cycle regulation and the development of cancer. Demonstrating that for normal cells to transform into neoplastic, oncogenes must interact directly with cyclins, determining deregulation of the cell cycle. Therefore, the onset of the neoplastic phenotype. [5] In 1992, he moved to Philadelphia, where he held the position of assistant professor at Temple University and then at Thomas Jefferson University. Since 2004, Giordano has been a full-time professor of Anatomy and Pathological Histology at the University of Siena and currently holds the position of director of the Sbarro Institute for Cancer Research and Molecular Medicine and of the Center for Biotechnology in the College of Science and Technology at Temple University. [6]
Since June 2006 for some years, Giordano has been president of the Scientific Committee of the Human Health Foundation Olus and president of the scientific committee for CROM (Oncological Research Center of Mercogliano-AV). There are also several collaborations with Italian universities, such as the Universities of Rome, Naples, Palermo, Messina, Sassari.
In 1993, Antonio Giordano identified and cloned a new tumor suppressor gene, RB2 / p130, which has a primary function in the cell cycle by controlling correct DNA replication and essentially preventing the onset of cancer. [7] The alterations, at the level of these tumor suppressor genes, that is their non-expression or a malfunction, allow the neoplastic cells to multiply in an uncontrolled way. In the year 2000, a study of great international scientific impact on lung cancer was completed. The absolute novelty consists in the first example of setting up a gene therapy model that is tested in vivo on the guinea pig animal (mouse) in which a lung tumor was induced. Using the functionally active RB2 / p130 gene, as a vector, a retrovirus, and tumor growth has been shown to be drastically reduced after a single injection of RB2 / p130. [8] In 2001, another study examined a topic of great relevance and scientific relevance. The results of this study have opened the doors to a very suggestive key to interpreting tumor pathogenesis. The experiments are always carried out on the animal (mouse) show, in fact, how RB2 / p130 can also work as an inhibitor of angiogenesis (the neoformation of vessels which, feeding the tumor, is the basis of neoplastic growth). In addition to RB2 / p130, Prof. Giordano has discovered two important "guardians" of the human genome CDK9 and CDK10 [9] The results obtained by prof. Giordano with these studies have had a wide echo in the international press, as they open up important perspectives in the field of cancer treatment, allow us to glimpse completely new application possibilities compared to traditional surgical and chemotherapeutic treatments. In 2004 Giordano discovered NSPs (Novel Structure Proteins), a new protein structure with a potential role in the dynamics of the nucleus during cell division. [10] One protein in particular (Isoform NSP5a3a) is highly expressed in the cell lines of some tumors and could be a very useful tumor marker.
In recent years, Giordano has dedicated numerous efforts to studying the relationship between cancer and environmental pollution in the Italian region of Campania, linking his career as a researcher to that of a science communicator. He was among the first to report an increased incidence of various types of cancer in populations near illegal toxic waste sites. Not only has he published scientific articles on this subject, but he has also committed himself to making these data known through two books on the subject, respectively "Campania, latera di Velini" [11] and "Munizza di stator" [12] [13] edited by Denaro Libri and Minerva respectively. It also launched a petition to protect the environment, signed by over 500 researchers and people from various professional sectors. He has also been the promoter of numerous non-profit initiatives aimed at safeguarding the environment and human health (for more information on Antonio Giordano's contribution to the topic of Health and Environment, also read his interview with Italian scientists and scientists from North America Foundation). Recently, as evidence of his commitment in this direction, Giordano was appointed Technical Consultant of the Public Prosecutor's Office of Avellino for the Iso Chimica [14] case and Scientific Director of the Mediterranea - Food and Wine Academy of Naples. He has carried out some scientific studies highlighting the anticancer properties of tomato. [15] Most recently he was the author and promoter of the Veritas [16] study, a pilot study aimed at clarifying the link between the onset of diseases and exposure to environmental pollutants.
Giordano is the author of over 600 scientific publications [17] on peer-reviewed journals and holds numerous international patents relating to the discovery of new genes and new methods for the diagnosis and treatment of cancer.
A tumor suppressor gene (TSG), or anti-oncogene, is a gene that regulates a cell during cell division and replication. If the cell grows uncontrollably, it will result in cancer. When a tumor suppressor gene is mutated, it results in a loss or reduction in its function. In combination with other genetic mutations, this could allow the cell to grow abnormally. The loss of function for these genes may be even more significant in the development of human cancers, compared to the activation of oncogenes.
Retinoblastoma (Rb) is a rare form of cancer that rapidly develops from the immature cells of a retina, the light-detecting tissue of the eye. It is the most common primary malignant intraocular cancer in children, especially those under 3 years old.
An oncovirus or oncogenic virus is a virus that can cause cancer. This term originated from studies of acutely transforming retroviruses in the 1950–60s, when the term oncornaviruses was used to denote their RNA virus origin. With the letters RNA removed, it now refers to any virus with a DNA or RNA genome causing cancer and is synonymous with tumor virus or cancer virus. The vast majority of human and animal viruses do not cause cancer, probably because of longstanding co-evolution between the virus and its host. Oncoviruses have been important not only in epidemiology, but also in investigations of cell cycle control mechanisms such as the retinoblastoma protein.
The Knudson hypothesis, also known as the two-hit hypothesis, is the hypothesis that most tumor suppressor genes require both alleles to be inactivated, either through mutations or through epigenetic silencing, to cause a phenotypic change. It was first formulated by Alfred G. Knudson in 1971 and led indirectly to the identification of tumor suppressor genes. Knudson won the 1998 Albert Lasker Clinical Medical Research Award for this work.
Alfred George Knudson, Jr. was an American physician and geneticist specializing in cancer genetics. Among his many contributions to the field was the formulation of the Knudson hypothesis in 1971, which explains the effects of mutation on carcinogenesis.
Carcinogenesis, also called oncogenesis or tumorigenesis, is the formation of a cancer, whereby normal cells are transformed into cancer cells. The process is characterized by changes at the cellular, genetic, and epigenetic levels and abnormal cell division. Cell division is a physiological process that occurs in almost all tissues and under a variety of circumstances. Normally, the balance between proliferation and programmed cell death, in the form of apoptosis, is maintained to ensure the integrity of tissues and organs. According to the prevailing accepted theory of carcinogenesis, the somatic mutation theory, mutations in DNA and epimutations that lead to cancer disrupt these orderly processes by interfering with the programming regulating the processes, upsetting the normal balance between proliferation and cell death. This results in uncontrolled cell division and the evolution of those cells by natural selection in the body. Only certain mutations lead to cancer whereas the majority of mutations do not.
Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is regulated by cyclins, more specifically by Cyclin D proteins and Cyclin-dependent kinase inhibitor proteins. The protein encoded by this gene is a member of the cyclin-dependent kinase, (CDK) family, which includes CDK4. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression in the point of regulation named R or restriction point.
Cyclin D1 is a protein that in humans is encoded by the CCND1 gene.
Retinoblastoma-like protein 2 is a protein that in humans is encoded by the RBL2 gene.
Transcription factor E2F4 is a protein that in humans is encoded by the E2F4 gene.
Runt-related transcription factor 3 is a protein that in humans is encoded by the RUNX3 gene.
Transcription factor E2F5 is a protein that in humans is encoded by the E2F5 gene.
Ubiquitin carboxyl-terminal hydrolase 6 (USB6), also termed TRE17 and Tre-2, is a deubiquitinating enzyme that in humans is encoded by the hominid USP6 gene located at band 13.2 on the short arm of chromosome 17. Deubiquitinating enzymes (DUBs) are enzymes that act within cells to remove ubiquitins from various functionally important proteins. Ubiquitin enzymes add ubiquitin to these proteins and thereby regulate their cellular location, alter their activity, and/or promote their degradation. By deubiquitinating these proteins, DUBs counter the effects of the ubiquinating enzymes and contribute to regulating the actions of the targeted proteins. In normal adult tissues, USP6 is highly expressed in testicle tissue, modestly expressed in ovarian tissue, and absent or minimally expressed in other tissues. It is also highly expressed in fetal brain tissue. The specific functions of USP6 are poorly defined primarily because its presence is restricted to primates: there are no available animal models to determine the effects of its deletion, although some studies suggest that UPSP6 contributes to normal brain development. In all events, USP6 has gained wide interest because of its abnormally increased expression by the neoplastic cells in various tumors derived from mesenchymal tissue.
AT rich interactive domain 4A (RBP1-like), also known as ARID4A, is a protein which in humans is encoded by the ARID4A gene.
Ubiquitin specific protease 4 (USP4) is an enzyme that cleaves ubiquitin from a number of protein substrates. Prior to the standardization of nomenclature USP4 was known as UNP, and was one of the first deubiquitinating enzymes to be identified in mammals. In the mouse and human the USP4 protein is encoded by a gene containing 22 exons.
Tyler Jacks is a David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT), a long-time HHMI investigator, and Founding Director of the David H. Koch Institute for Integrative Cancer Research, which brings together biologists and engineers to improve detection, diagnosis, and treatment of cancer. Dr. Jacks is a member of the board of directors of Thermo Fisher Scientific and Amgen, two of the major biotechnology corporations in the world. He is the President of Break Through Cancer and a member of the Board of Overseers, the larger of two governing boards of Harvard University.
The retinoblastoma protein is a tumor suppressor protein that is dysfunctional in several major cancers. One function of pRb is to prevent excessive cell growth by inhibiting cell cycle progression until a cell is ready to divide. When the cell is ready to divide, pRb is phosphorylated, inactivating it, and the cell cycle is allowed to progress. It is also a recruiter of several chromatin remodeling enzymes such as methylases and acetylases.
The triangle of death is an area approximately 25 km northeast of the city of Naples in the Province of Naples, Campania, Italy, that comprises the comuni of Acerra, Nola and Marigliano. This area contains the largest illegal waste dump in Europe due to a waste management crisis in the 1990s and 2000s.
Ed Harlow is an American molecular biologist.
J. William Harbour is an American ophthalmologist, ocular oncologist and cancer researcher. He is Chair of the Department of Ophthalmology at the University of Texas Southwestern Medical Center in Dallas. He previously served as the vice chair and director of ocular oncology at the Bascom Palmer Eye Institute and associate director for basic science at the Sylvester Comprehensive Cancer Center of the University of Miami's Miller School of Medicine.